Core Laboratories (NYSE:CLB) Stake Lifted by WCM Investment Management CA

WCM Investment Management CA increased its holdings in shares of Core Laboratories (NYSE:CLB) by 5.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,793,731 shares of the oil and gas company’s stock after buying an additional 250,830 shares during the quarter. Core Laboratories accounts for approximately 5.9% of WCM Investment Management CA’s holdings, making the stock its 7th largest holding. WCM Investment Management CA owned 10.86% of Core Laboratories worth $525,153,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Robeco Institutional Asset Management B.V. grew its holdings in shares of Core Laboratories by 60.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 1,096 shares of the oil and gas company’s stock valued at $120,000 after acquiring an additional 414 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Core Laboratories by 63.7% during the second quarter. The Manufacturers Life Insurance Company now owns 1,128 shares of the oil and gas company’s stock worth $114,000 after purchasing an additional 439 shares during the period. Advisory Services Network LLC grew its holdings in Core Laboratories by 33.3% during the second quarter. Advisory Services Network LLC now owns 1,365 shares of the oil and gas company’s stock worth $138,000 after purchasing an additional 341 shares during the period. Callahan Advisors LLC bought a new position in Core Laboratories during the fourth quarter worth about $201,000. Finally, Toronto Dominion Bank grew its holdings in Core Laboratories by 243.6% during the third quarter. Toronto Dominion Bank now owns 1,866 shares of the oil and gas company’s stock worth $184,000 after purchasing an additional 1,323 shares during the period.

Shares of Core Laboratories (NYSE CLB) traded down $0.16 during midday trading on Thursday, hitting $105.59. 438,745 shares of the stock traded hands, compared to its average volume of 450,948. Core Laboratories has a 52-week low of $86.55 and a 52-week high of $121.39. The firm has a market capitalization of $4,650.00, a price-to-earnings ratio of 56.05 and a beta of 1.44. The company has a quick ratio of 1.66, a current ratio of 1.98 and a debt-to-equity ratio of 1.53.

Core Laboratories (NYSE:CLB) last posted its earnings results on Wednesday, January 31st. The oil and gas company reported $0.58 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.58. Core Laboratories had a net margin of 12.60% and a return on equity of 58.25%. The company had revenue of $172.00 million for the quarter, compared to analyst estimates of $171.92 million. During the same quarter in the prior year, the business posted $0.41 EPS. The firm’s revenue was up 15.1% compared to the same quarter last year. sell-side analysts forecast that Core Laboratories will post 2.67 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 16th. Shareholders of record on Friday, January 26th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Thursday, January 25th. This represents a $2.20 annualized dividend and a yield of 2.08%. Core Laboratories’s dividend payout ratio (DPR) is 117.02%.

A number of brokerages have recently issued reports on CLB. TheStreet upgraded Core Laboratories from a “c” rating to a “b-” rating in a report on Thursday, February 1st. Zacks Investment Research downgraded shares of Core Laboratories from a “hold” rating to a “sell” rating in a research report on Monday, February 5th. Royal Bank of Canada set a $125.00 price objective on shares of Core Laboratories and gave the company a “buy” rating in a research report on Tuesday, January 30th. Deutsche Bank downgraded shares of Core Laboratories from a “buy” rating to a “hold” rating and lowered their price objective for the company from $116.30 to $109.00 in a research report on Thursday, January 11th. Finally, ABN Amro cut shares of Core Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $111.70.

WARNING: This report was posted by Week Herald and is the property of of Week Herald. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://weekherald.com/2018/02/15/wcm-investment-management-ca-buys-250830-shares-of-core-laboratories-clb.html.

Core Laboratories Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply